Gross Profit (TTM) Chart

View Gross Profit (TTM) for RLAY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Gross Profit (TTM) Chart
Start Trial

Historical Gross Profit (TTM) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 8.139M
March 31, 2026 7.824M
December 31, 2025 11.80M
September 30, 2025 4.064M
June 30, 2025 3.445M
March 31, 2025 2.402M
December 31, 2024 4.543M
September 30, 2024 4.502M
June 30, 2024 29.71M
March 31, 2024 29.86M
December 31, 2023 20.28M
September 30, 2023 20.74M
June 30, 2023 -3.788M
March 31, 2023 -3.164M
December 31, 2022 -2.749M
Date Value
September 30, 2022 -2.303M
June 30, 2022 -1.614M
March 31, 2022 -1.023M
December 31, 2021 -0.467M
September 30, 2021 81.74M
June 30, 2021 80.83M
March 31, 2021 79.96M
December 31, 2020 79.10M
September 30, 2020 -3.49M
June 30, 2020 -3.211M
March 31, 2020 -3.037M
December 31, 2019 -2.845M
September 30, 2019 -1.992M
June 30, 2019 -1.358M
March 31, 2019 -0.667M

Gross Profit Definition

Annual, Interim and Preliminary Items - Commercial, Other Financial Companies

Read full definition.

Gross Profit (TTM) Range, Past 5 Years

View Gross Profit (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit (TTM) Benchmarks

View Gross Profit (TTM) Benchmarks
Start Trial
AbbVie, Inc. 45.98B
TG Therapeutics, Inc. 658.60M
Karyopharm Therapeutics, Inc. 140.44M
Krystal Biotech, Inc. 411.03M
Akebia Therapeutics, Inc. 172.88M